OptimizeRx Corporation Third Quarter 2026 Conference Call - OPTIMIZERX CORP

Explicit Guidance:

• FY2026 Revenue: Updated to a range of $87 million to $93 million (previously higher; reflects contracted revenue tracking ~20% below prior year and timing of Q4 recognition).
• FY2026 Adjusted EBITDA: Maintained at $21 million to $25 million.
• FY2026 Gross Margins: Expected to be in the low 70% range for the full year, driven by margin optimization and cost reduction initiatives.
• FY2027 Contracted Revenue: Currently tracking approximately 20% ahead year-over-year for the RFP season; projected growth rates expected to resemble FY2025 levels rather than FY2026, though specific FY2027 guidance is not yet provided.
• Debt Reduction: Intention to continue paying down debt ahead of schedule, with a current balance of $10.4 million (post-Q3 paydown).
• Share Repurchases: Intent to increase activity on stock buybacks in Q4 and beyond as debt is serviced.

Business-Segment Outlook:

• Customer Cohorts & Retention: Net Revenue Retention (NRR) dipped to 83% in Q3 but is expected to normalize and exceed 100% in 2027 following the return of a previously displaced top-tier client. Mid-tier and long-tail clients are showing "exceptionally good play," with some moving into the top 10 client pool; growth in this segment estimated at double digits YoY.
• Product Portfolio Expansion:
  • NLAB (Natural Language Audience Builder): Enhanced to include privacy-safe direct-to-consumer audiences alongside HCP targeting in September, enabling unified omni-channel workflows.
  • COPEQ Solution: Newly introduced to expand audience engagement capabilities.
  • DAP (Demand-Activation Platform): Continued scaling of AI-enabled audience intelligence.
• Revenue Recognition Timing: Significant portion of FY2026 revenue to be recognized in Q4 to meet the revised guidance range; Q4 is expected to see a "turn" in KPIs as pent-up demand converts.

Market and Competitive Outlook:

• Programmatic Distribution: Partnerships with DeepIntent, The Trade Desk, and PulsePoint established; management estimates these three DSPs represent 60–70% of the programmatic volume.
  • Trade Desk Integration: Provides access to 800,000+ verified healthcare professionals across 400+ EHR/e-prescribing systems.
  • PulsePoint Integration: Expected to contribute 250,000 incremental NPIs to the network; inventory expected to be live for advertisers in November.
• Competitive Moat: Differentiation cited via proprietary AI-enabled platform, authenticated clinical data, and a network of 1.1+ million verified HCPs across 450+ EHR systems.
• Pricing & Demand: Underlying demand remains strong due to customer need for precise targeting and measurable ROI; however, spending normalization in 2027 is contingent on the resolution of macro/policy uncertainty.
• Industry Shift: Anticipated shift toward programmatic healthcare advertising and AI-driven planning, with EHR inventory moving from direct sales to omni-channel programmatic buying.

Macro / Industry Outlook:

• Pharma Spending Environment: Clients navigating budget scrutiny and "evolving spending priorities"; significant "warehouse" of unspent dollars (pent-up demand) anticipated to deploy in late 2026/Q1 2027.
• Regulatory & Policy Risks: Clients uncertain regarding the impact of the US election outcome (shift from Republican to Democratic control) and ongoing MFN (Minimum Fairness in Pricing) legislation; this uncertainty contributed to Q3 spending delays.
• Seasonality: Q4 historically associated with accelerated spending and year-end budget utilization ("use it or lose it" dollars).

Strategic Initiatives:

• Commercial Leadership: Appointment of Sarah Bass as Chief Marketing Officer in Q3 to strengthen go-to-market execution and deepen agency/pharma relationships.
• Finance Leadership Transition: Andy DeSilva to assume CFO role and Heather Favazza to become Chief Accounting Officer effective January 1, 2027; outgoing CFO Ed Stelmach to remain as strategic advisor through year-end.
• Capacity & Network Expansion: Ongoing integration of programmatic DSPs to expand distribution footprint and eliminate barriers to entry for EHR advertising in broader media plans.
• Tech Investment: Continued scaling of AI and patent-protected DAP/NLAB technologies to drive scalability without proportional cost increases.

Risks and Headwinds to Outlook:

• Revenue Recognition Risk: Full achievement of FY2026 revenue guidance depends on converting pipeline opportunities and recognized revenue within the final six weeks of the quarter; "buy-up" activity remains a key variable.
• Customer Concentration: History of reliance on a limited number of large customers; specifically, the return of a single displaced client (representing ~10 points of NRR and significant historical revenue) is critical to 2027 recovery.
• Spending Uncertainty: Timing of customer spending decisions remains difficult to predict due to macroeconomic and regulatory ambiguity.
• Execution Risk: Failure to convert contracted revenue into recognized revenue before year-end could result in missing the revised top-end of the guidance range.
• Competition & Tech: Risks associated with maintaining EHR contracts, cybersecurity, and keeping pace with evolving technology/AI capabilities.

Management Tone on the Future:

• Confidence Level: Management expresses strong confidence in the long-term market opportunity and the FY2027 outlook, citing "very encouraging" signs in the RFP season and client engagement.
• Tone: Cautiously optimistic regarding FY2026 finalization (downside risk managed by guidance revision) but highly positive on the structural improvements and growth trajectory for 2027 ("mojo on the team... is the best it's been in a very long time").
• Guidance Revision: The FY2026 revenue cut is framed as a reflection of "timing and conversion" rather than a change in the long-term market opportunity, emphasizing discipline over over-promise.

Miscellaneous:

• Debt Status: Outstanding debt reduced to $10.4 million as of September 30, 2026 (following $6.3M principal payment in Q3 and additional $3M post-quarter); interest rate is SOFR + 2.25% on $13.4M (pre-paydown) term loan.
• Cash Position: Ended Q3 2026 with $22.3 million in cash.
• Operating Efficiency: Revenue per FTE stood at $706,000; operating expenses decreased $5.1 million YoY despite severance costs.
• Dividends: No mention of dividends; focus is on debt paydown and share buybacks.